AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

AC Immune S.A.NASDAQ: ACIU

Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Financing cash flow growth accelerates

Q4 FY2025 financing cash flow of CHF 259.95K (cash outflow) rose 32.0% year over year, ahead of the -9.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at -10.2% a year.

Context

  • Financing cash flow amounted to 27.3% of revenue in FY2025, up 23.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +32.0% holds above the trailing-twelve-month pace of -9.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CHF 259.95K+2.3% QoQ
Last fiscal yearDec 2025
-CHF 974.14K-13.0% YoY
LTMDec 2025
-CHF 1.02M-9.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.0%——
1 year-13.0%——
3-year CAGR-10.2%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CHF · from the cash flow

Latest · FY2025
(974.14K) CHF
Year-over-year change
+13.0%

Financing Cash Flow vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.0% is the 6th highest of 9, against a peer median of +6.8%.
  • Financing cash flow amounts to 28.5% of revenue for ACIU, versus a peer median of 19.1%.
ACIU Competitors
Financing Cash Flow for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANROAlto Neuroscience, Inc.LTM Mar 2026$165.89M USD+1517.0%+11.1%—
ANNXAnnexon, Inc.LTM Mar 2026$141.69M USD+10.0%-4.0%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$112.79M USD+3.6%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$102.13M USD+7755.9%+68.0%329441.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$45.77M USD—-22.1%—
CLLSCellectis S.A.LTM Mar 2026$17.39M USD-123.8%—25.5%
AMRNAmarin Corporation plcLTM Mar 2026$2.59M USD+127.8%+75.3%1.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.02M CHF-9.0%-10.2%28.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$191.89K USD-76.4%-2.7%—
MREOMereo BioPharma Group plcLTM Mar 2026$95.27K USD-100.2%+17.8%19.1%
SLNSilence Therapeutics plcLTM Mar 2026$911.01 USD—-93.4%0.1%
Peer median (excluding ACIU) —+6.8%+4.2%19.1%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.